List of Excipients in Branded Drug FRUZAQLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	CELLULOSE, MICROCRYSTALLINE	2032-03-23
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	FD&C YELLOW NO. 5	2032-03-23
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	FD&C YELLOW NO. 6	2032-03-23
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	GELATIN	2032-03-23
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	STARCH, CORN	2032-03-23
Takeda Pharmaceuticals America Inc	FRUZAQLA	fruquintinib	63020-210	TALC	2032-03-23

FRUZAQLA Excipient Strategy and Commercial Opportunities in Fruquintinib

Last updated: September 14, 2026

FRUZAQLA (fruquintinib) is an oral, small-molecule VEGFR inhibitor approved by the FDA for adults with metastatic colorectal cancer previously treated with standard chemotherapy, anti-VEGF therapy, and, where applicable, anti-EGFR therapy.[1] Its commercial formulation is a low-dose hard gelatin capsule containing conventional excipients. The largest near-term excipient opportunities are supply-chain redundancy, capsule-shell optimization, global formulation harmonization, and lifecycle products that improve administration or manufacturing economics.

Fruquintinib is not a biologic, so biosimilar competition does not apply. Future competition will come from generic small-molecule applicants, formulation differentiation, alternative dosage forms, and competing colorectal cancer therapies.

What is FRUZAQLA and how is it formulated?

FRUZAQLA is supplied as 1 mg and 5 mg hard gelatin capsules. The recommended dosage is 5 mg orally once daily for 21 consecutive days followed by seven days off treatment, repeated in 28-day cycles.[1]

Attribute	FRUZAQLA commercial profile
Active ingredient	Fruquintinib
Drug class	Selective VEGFR inhibitor
Dosage form	Immediate-release hard gelatin capsule
Strengths	1 mg and 5 mg
Administration	Oral, once daily for 21 days of a 28-day cycle
U.S. approval	November 8, 2023
FDA indication	Previously treated metastatic colorectal cancer
Sponsor	Takeda Pharmaceuticals
Original developer	HUTCHMED
Small-molecule or biologic	Small molecule
Biosimilar pathway	Not applicable
Key formulation characteristic	Low-dose solid oral capsule

The labeled capsule-fill excipients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The capsule shell contains gelatin, titanium dioxide, and iron oxide colorants.[1]

The formulation uses a standard direct-compression or capsule-fill excipient platform. It does not depend on a novel delivery system, modified-release matrix, lipid vehicle, amorphous solid dispersion, or device component disclosed in the U.S. prescribing information.

What excipients are used in FRUZAQLA capsules?

The principal excipients have distinct functional roles:

Excipient	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and bulk carrier	Broad availability; potential source of supplier and allergen-management issues
Microcrystalline cellulose	Diluent, flow aid, and compaction support	Supports robust capsule-fill performance
Croscarmellose sodium	Superdisintegrant	Supports rapid capsule-content dispersion
Colloidal silicon dioxide	Glidant and flow-control agent	Important for low-dose blend uniformity
Magnesium stearate	Lubricant	Can affect dissolution, powder flow, and blend uniformity if overused
Gelatin	Capsule-shell polymer	Creates animal-origin, religious-certification, and supply-chain considerations
Titanium dioxide	Opacifier and pigment	Regulatory restrictions differ by jurisdiction
Iron oxides	Capsule-shell colorants	Supports strength and product identification

The most important technical issue is not dissolution alone. Fruquintinib is administered at a low dose relative to the total capsule fill, so blend uniformity and content uniformity are central manufacturing controls. Poor powder segregation, excessive lubrication, or inconsistent particle-size distribution could affect potency uniformity.

How strong is the current excipient strategy?

The current strategy is commercially efficient but not highly differentiated. It uses established excipients with established regulatory histories and avoids complex formulation technologies.

Advantages

The formulation has several operational benefits:

1. It uses common pharmaceutical-grade excipients.
2. It supports conventional capsule manufacturing.
3. It avoids specialized equipment associated with hot-melt extrusion, spray drying, or multiparticulate systems.
4. It permits two strengths using a relatively simple product architecture.
5. It creates a comparatively low barrier for generic manufacturers that can reproduce the dosage form and demonstrate bioequivalence.

The 1 mg strength is commercially important even though the standard dose is 5 mg. It can support dose reduction for toxicity management, which is relevant because hypertension, hand-foot syndrome, fatigue, and other adverse reactions may require interruption or dose modification.[1]

Limitations

The formulation also has vulnerabilities:

• Gelatin creates animal-origin and vegetarian-market limitations.
• Titanium dioxide is subject to different regulatory positions across markets.
• Lactose may constrain products targeting patients with excipient sensitivities, although the amount in the final capsule may be clinically small.
• Conventional capsules provide limited differentiation against generic copies.
• The formulation does not create a strong barrier against alternative capsule-fill processes.
• A generic applicant may be able to use qualitatively and quantitatively different excipients if it satisfies applicable quality and bioequivalence requirements.

A formulation that is operationally simple is attractive for supply and cost control, but simplicity also reduces formulation-based exclusivity.

What excipient opportunities exist for FRUZAQLA lifecycle management?

The strongest opportunities are alternative capsules, excipient substitution, and manufacturing improvements rather than a radical new delivery platform.

Hypoallergenic and non-animal capsules

A hydroxypropyl methylcellulose capsule could support:

• vegetarian and halal positioning;
• avoidance of bovine or porcine gelatin;
• improved access to markets with animal-origin restrictions;
• greater control over moisture transmission in selected packaging configurations.

A capsule-shell change would require comparative quality work, dissolution testing, stability studies, and potentially a regulatory supplement or variation, depending on the jurisdiction and extent of the change.

Titanium-dioxide-free shells

A titanium-dioxide-free capsule could reduce regulatory complexity in jurisdictions that restrict or scrutinize titanium dioxide in oral products. Iron oxides, mineral pigments, or approved organic colorants may provide alternative identification systems.

The business case is strongest for global products. A single shell specification that avoids jurisdiction-specific colorant changes can reduce manufacturing complexity and inventory fragmentation.

Lactose-free or reduced-lactose formulations

A lactose-free formulation could use mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable diluent. The opportunity is primarily market-access and patient-positioning rather than a likely major clinical advantage.

Any substitution must preserve:

• blend uniformity at the 1 mg strength;
• capsule-fill weight;
• disintegration;
• dissolution;
• chemical stability;
• moisture control;
• compatibility with fruquintinib.

Mannitol may offer a useful alternative where lactose avoidance is commercially important, but its flow, density, and moisture behavior would need to be evaluated against the existing formulation.

Direct-compression and continuous-manufacturing optimization

Fruquintinib’s low dose makes process control valuable. Potential improvements include:

• engineered excipient particle-size distributions;
• ordered mixing or carrier-based blending;
• reduced segregation during transfer;
• optimized lubricant concentration;
• near-infrared or process analytical technology for blend monitoring;
• continuous powder blending and capsule filling.

These changes may not produce a patient-visible benefit, but they can reduce yield loss, improve batch consistency, and support manufacturing at lower cost.

Pediatric or flexible-dose presentations

The current indication is adult metastatic colorectal cancer, so pediatric demand is limited. A future flexible-dose product could still address:

• dose titration after toxicity;
• patients with difficulty swallowing capsules;
• administration through a validated extemporaneous or multiparticulate platform;
• dose levels below 1 mg if clinical practice creates demand.

A liquid, sprinkle, mini-tablet, or orally disintegrating product would require new stability and bioequivalence data. The commercial value would depend on expanded use, not merely convenience.

What patents and exclusivity protect FRUZAQLA?

FRUZAQLA benefits from regulatory exclusivity and patent protection, but the product is not protected in the same way as a complex biologic.

Protection category	Position
FDA approval	November 8, 2023
New chemical entity exclusivity	Generally five years from approval, subject to statutory exceptions
Estimated U.S. NCE exclusivity endpoint	November 8, 2028
Patent protection	Must be assessed through current FDA Orange Book listings and relevant patent records
Biosimilar protection	Not applicable
Generic pathway	ANDA, including possible Paragraph IV certification
Formulation differentiation	Limited based on the conventional capsule formulation disclosed in the label

The five-year NCE period generally prevents an ANDA from being submitted for four years and may restrict approval until five years after approval, subject to a qualifying Paragraph IV certification.[2] The NCE period should not be treated as the product’s full patent term.

The commercial duration will depend on the composition-of-matter, salt, polymorph, formulation, method-of-use, and manufacturing patents covering fruquintinib. The current Orange Book should control the list of patents and statutory expiration dates because patent term adjustment, terminal disclaimers, pediatric extensions, and listing changes can affect the relevant endpoint.[3]

What formulation patents could affect generic entry?

Potentially relevant formulation claims could cover:

• a specific fruquintinib-to-excipient ratio;
• capsule composition;
• particle-size or polymorph specifications;
• dissolution performance;
• methods for achieving content uniformity;
• treatment regimens involving dose interruption or dose reduction;
• manufacturing methods that control impurity levels.

A generic applicant may avoid infringement risk by using different excipients or process parameters. That makes formulation patents most valuable when they claim a necessary performance attribute rather than a narrow, easily designed-around ingredient list.

When does FRUZAQLA lose exclusivity?

The most visible U.S. regulatory milestone is the NCE endpoint in November 2028. Actual generic entry could occur later if relevant patents remain enforceable or if litigation and settlement agreements delay launch.

Generic entry scenarios

Scenario	Commercial effect
No viable Paragraph IV challenge before NCE expiry	Generic applications may progress after the statutory exclusivity barrier, subject to patent status
Paragraph IV litigation with a 30-month stay	FDA approval may be delayed during the statutory stay unless resolved earlier
Patent settlement with an authorized generic	Entry date and price erosion depend on settlement terms
Successful patent invalidity or non-infringement decision	Earlier generic risk
Formulation redesign by generic applicant	May reduce infringement exposure while preserving ANDA viability
Multiple generic entrants after launch	Greater price pressure and faster market-share erosion

No biosimilar litigation pathway applies because fruquintinib is a chemically synthesized small molecule. The relevant challenge mechanism is the ANDA process, not a 351(k) biologics application.

What is the FDA regulatory status and Orange Book position?

The FDA approved FRUZAQLA under the NDA pathway for adults with metastatic colorectal cancer after prior therapies.[1] The approval was supported by the FRESCO-2 and FRESCO trials, which evaluated fruquintinib in previously treated colorectal cancer populations.[1]

The product’s Orange Book relevance is based on NDA-linked patents and exclusivity. A prospective entrant would need to evaluate:

• listed patents and their expiration dates;
• whether any patent claims cover the approved strength or dosage regimen;
• Paragraph IV certification exposure;
• 30-month stay risk;
• potential pediatric exclusivity;
• state substitution and labeling requirements;
• manufacturing-site and drug-substance qualification.

Because the capsule formulation is conventional, excipient differences alone may not remove all patent risk. Method-of-use claims may remain relevant even if a generic uses a different diluent, lubricant, or capsule shell.

What licensing deals affect FRUZAQLA?

Takeda licensed global rights to fruquintinib outside mainland China, Hong Kong, and Macau from HUTCHMED in January 2023. The announced transaction included a $400 million upfront payment, potential milestone payments of up to $730 million, and tiered royalties on net sales.[4]

Transaction element	Disclosed term
Licensee	Takeda
Licensor	HUTCHMED
Geographic scope	Global rights outside mainland China, Hong Kong, and Macau
Upfront payment	$400 million
Potential milestones	Up to $730 million
Royalties	Tiered royalties on net sales

The deal creates commercial incentives for both companies to extend the product’s lifecycle. Excipient improvements that lower cost of goods, simplify global registration, or support new presentations can increase the value of the licensed asset without changing the active ingredient.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target five areas.

Dual sourcing and supply security

Lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, gelatin, and capsule colorants are all candidates for qualified alternate suppliers. A supplier that can provide consistent particle-size distribution, low bioburden, validated change control, and global regulatory documentation has a stronger opportunity than a low-price commodity supplier.

High-purity low-dose blending

The 1 mg capsule creates a technical opportunity for excipient platforms designed for low-dose uniformity. Useful attributes include controlled density, narrow particle-size distribution, low electrostatic charging, and predictable flow.

Vegan and global-compliance capsule shells

HPMC shells, titanium-dioxide-free shells, and globally standardized color systems could support market expansion and reduce jurisdiction-specific packaging or manufacturing requirements.

Functional excipient substitution

Mannitol, silicified microcrystalline cellulose, co-processed excipients, and improved glidant systems could be evaluated for better flow, lower blend segregation, or more efficient capsule filling.

Contract development and manufacturing

CDMOs with expertise in potent oral solid dosage products can offer formulation bridging, process validation, analytical method transfer, and global post-approval change management. The low dose and oncology indication make containment, cleaning validation, and cross-contamination controls commercially relevant.

How does FRUZAQLA compare with competing colorectal cancer drugs?

FRUZAQLA competes with other later-line therapies rather than with one identical formulation.

Product	Active ingredient	Dosage form	Commercial differentiation
FRUZAQLA	Fruquintinib	Capsule	Selective VEGFR inhibition; once-daily oral dosing
LONSURF	Trifluridine/tipiracil	Tablet	Oral cytotoxic combination
STIVARGA	Regorafenib	Tablet	Multikinase inhibitor; established colorectal cancer use
CABOMETYX	Cabozantinib	Tablet	Multikinase inhibitor with other oncology indications
Avastin and biosimilars	Bevacizumab	Intravenous biologic	Infusion-based anti-VEGF therapy

FRUZAQLA’s capsule platform is less formulation-complex than intravenous biologics and less differentiated than controlled-release or device-enabled products. Its commercial value rests primarily on clinical positioning, tolerability management, global licensing, and protection of the active ingredient and treatment method.

What revenue exposure and generic risk should investors monitor?

Commercial exposure depends on the share of revenue generated in the United States and other licensed territories, the duration of patent protection, and the speed of generic uptake after entry.

Key indicators include:

• quarterly FRUZAQLA net sales reported by Takeda;
• prescription growth in metastatic colorectal cancer;
• payer access and prior-authorization requirements;
• dose intensity and treatment persistence;
• market share against trifluridine/tipiracil and regorafenib;
• new indications or combination studies;
• Orange Book additions or removals;
• Paragraph IV notifications;
• settlement agreements;
• supply commitments for active ingredient and capsule materials.

The formulation itself is unlikely to prevent generic competition. Its strongest commercial defenses are regulatory exclusivity, patent claims, clinical adoption, manufacturing reliability, and potential expansion into additional tumor types.

Key Takeaways

• FRUZAQLA is a conventional immediate-release hard gelatin capsule containing fruquintinib.
• The labeled excipients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, with a gelatin-based colored shell.
• The principal formulation risk is low-dose blend uniformity, not complex drug delivery.
• The highest-value excipient opportunities are HPMC shells, titanium-dioxide-free shells, lactose-free diluents, engineered low-dose blending systems, and dual sourcing.
• U.S. NCE exclusivity is expected to run through November 8, 2028, subject to statutory conditions.
• Fruquintinib is a small molecule, so biosimilar competition does not apply.
• Generic entry will depend on ANDA timing, Paragraph IV certifications, Orange Book patents, litigation, and settlement terms.
• Takeda’s license from HUTCHMED includes a $400 million upfront payment, up to $730 million in potential milestones, and tiered royalties.
• The formulation has limited intrinsic differentiation, so long-term commercial value depends more heavily on patents, clinical positioning, and market expansion.

FAQs About FRUZAQLA Excipients and Commercialization

Can FRUZAQLA be reformulated as a vegetarian capsule?

Yes. A hydroxypropyl methylcellulose capsule could replace gelatin, subject to comparative quality, stability, dissolution, and regulatory-change requirements.

Is FRUZAQLA a biologic that can face biosimilar competition?

No. Fruquintinib is a chemically synthesized small molecule. Competition would proceed through generic-drug pathways, including ANDAs and possible Paragraph IV certifications.

Which excipient is most important for FRUZAQLA content uniformity?

The combined diluent and flow system is most important. Lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate collectively affect segregation, flow, lubrication, and low-dose blend uniformity.

Could a generic manufacturer use different FRUZAQLA excipients?

Generally, yes, if the product meets applicable bioequivalence, quality, stability, dissolution, and regulatory requirements. Different excipients do not automatically eliminate method-of-use or composition patent risks.

What is the most attractive lifecycle product opportunity for fruquintinib?

A globally harmonized capsule platform using a non-animal, titanium-dioxide-free shell and an optimized low-dose blend is the most practical near-term opportunity. A liquid or orally disintegrating formulation would offer greater differentiation but would require a stronger clinical and commercial rationale.

References

1. U.S. Food and Drug Administration. (2023). FRUZAQLA (fruquintinib) capsules: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). New chemical entity exclusivity. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. HUTCHMED. (2023, January 9). HUTCHMED enters into licensing agreement with Takeda for fruquintinib outside China. HUTCHMED.